August 3, 2026, marks the deadline for investors to seek lead plaintiff status in a securities fraud class action against GeneDx Holdings Corp. The lawsuit alleges the company made false statements regarding its financial health and the Fabric Genomics acquisition between April 2025 and May 2026.
These allegations stem from GeneDx's first-quarter 2026 results, which included lowered full-year earnings guidance. The company also reported a significant decline in adjusted gross margin during that period.
GeneDx shares plummeted nearly 50% on May 5, 2026, following the announcement. The company is scheduled to release its second-quarter 2026 financial results today after the market closes.